Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC
Status:
Enrolling by invitation
Trial end date:
2023-09-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of concurrent radiotherapy
with Apatinib in patients with Brain Metastases from drive gene wide-type Non-small-cell Lung
Cancer (NSCLC).